GLP-1 Drug Manufacturers for Weight Loss

Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Five major pharmaceutical companies currently produce FDA-approved GLP-1 medications for weight loss: Novo Nordisk (semaglutide, tirzepatide), Eli Lilly (tirzepatide, retatrutide), Viking Therapeutics, Structure Therapeutics, and Amgen. Each manufacturer brings different formulations, dosing schedules, and clinical efficacy profiles to the market.

Beyond brand names and manufacturers, your individual response to GLP-1 therapy depends on genetics, metabolic biomarkers, and peptide receptor sensitivity. PlexusDx's precision-wellness approach helps you understand your metabolic predispositions, enabling more informed conversations with providers about which GLP-1 option may align with your physiology.

Major GLP-1 Manufacturers and Their Product Lines

Novo Nordisk leads the GLP-1 market with semaglutide (Ozempic for diabetes, Wegovy for weight loss) and tirzepatide under license partnerships. Semaglutide is administered once weekly via injection or daily oral formulation. Clinical trials show approximately 15-22% weight reduction over 68 weeks with semaglutide in weight-management studies.

Eli Lilly manufactures tirzepatide (Zepbound for weight loss, Mounjaro for diabetes), a dual GIP/GLP-1 receptor agonist showing superior weight loss compared to semaglutide monotherapy in head-to-head trials. Eli Lilly also developed retatrutide, a triple-hormone receptor agonist (GLP-1/GIP/glucagon) currently in late-stage trials, with interim data suggesting up to 24% weight reduction.

Manufacturer Comparison: Formulation, Mechanism, and Clinical Evidence

Each manufacturer's GLP-1 product differs in receptor selectivity, pharmacokinetics, and demonstrated efficacy. Direct comparisons help contextualize why provider selection depends on individual metabolic factors, not brand alone. The table below outlines key clinical distinctions across major products.

Manufacturer	Product (Active)	Mechanism	Weight Loss Data	Formulation
Novo Nordisk	Semaglutide (Wegovy)	GLP-1R agonist	15-22% over 68 weeks	Weekly injection or daily oral
Eli Lilly	Tirzepatide (Zepbound)	GIP/GLP-1 dual agonist	20-22.5% over 72 weeks	Weekly injection
Eli Lilly	Retatrutide (investigational)	GLP-1/GIP/glucagon triple	Up to 24% (interim data)	Weekly injection (in trials)
Viking/Amgen	VK2735 & MariTide (investigational)	GLP-1/GIP dual agonist	14-21% (interim data)	Investigational formulations

How Genetic Factors Influence GLP-1 Response Beyond Manufacturer

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), and GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to GLP-1 medications or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Weight-regulation genes like FTO rs9939609 and MC4R rs17782313 influence baseline metabolic dysfunction and appetite signaling. Understanding your genetic predispositions in peptide pathways allows providers to tailor GLP-1 selection more strategically, rather than defaulting to whichever manufacturer is most marketed.

Safety, Eligibility, and Clinical Decision-Making with Your Provider

GLP-1 medications carry shared side effects across manufacturers: nausea, vomiting, constipation, and gastrointestinal upset, particularly during dose escalation. Contraindications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or severe renal/hepatic impairment. Your healthcare provider must evaluate your medical history regardless of which manufacturer's product you consider.

Provider selection of a GLP-1 medication should balance efficacy data, your metabolic profile, genetic predispositions, affordability, and injection/oral preference. Compounded formulations from licensed 503A pharmacies offer additional cost-effective options. A qualified provider can help interpret your biomarker and genetic test results in context of manufacturer choice, ensuring alignment with your health goals.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context on your predispositions in GLP1R, GIPR, and weight-regulation gene variants (FTO, MC4R). This information can support a more informed conversation with your provider about which GLP-1 manufacturer and formulation may align best with your metabolic genetics.

The genetic test reveals predispositions in peptide receptor pathways—not exact medication response. Variants like GLP1R rs6923761 and GIPR rs1800437 can inform provider discussions about dual-agonist versus single-agonist formulations, but results should be interpreted with a qualified healthcare provider who understands your complete clinical picture.

PlexusDx compounded semaglutide and tirzepatide injections offer cost-effective alternatives to branded medications, at $189/mo month-to-month, or from $149/mo on the 6-month plan per month from licensed 503A compounding pharmacies. Combined with genetic testing and provider guidance, this precision approach enables personalized GLP-1 selection informed by your peptide pathway predispositions, not manufacturer marketing alone.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which brand names map to diabetes versus weight management in this article?

The article pairs Ozempic with diabetes and Wegovy with weight loss, both semaglutide products from Novo Nordisk. On the Eli Lilly side it pairs Mounjaro with diabetes and Zepbound with weight management, both tirzepatide. The distinction matters because the same molecule is sold under two names with two different approved uses, and the article treats that choice as a clinical decision rather than a shopping one.

What is retatrutide and how far along is it, according to this article?

Retatrutide is described as a triple-hormone receptor agonist acting on GLP-1, GIP, and glucagon pathways, developed by Eli Lilly. The article places it in late-stage trials with interim data only, and its own comparison table marks it investigational. That means it is not an approved product anyone can be prescribed today, and PlexusDx does not offer it.

Which experimental candidates appear in this article's manufacturer comparison table?

The table lists VK2735 and MariTide, both described as dual GLP-1 and GIP agonists with interim data only and investigational formulations. They sit alongside approved products in the same table but are explicitly flagged as not yet available. The article uses them to show how crowded the development pipeline has become, not to suggest either can be obtained now.

Do side effects differ depending on which manufacturer's product someone takes?

The article says the core side effects are shared across manufacturers: nausea, vomiting, constipation, and general gastrointestinal upset, particularly during dose escalation. Contraindications are also common across the class, including a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, and severe renal or hepatic impairment. A provider must review your history whichever product is under discussion.

Beyond headline efficacy figures, what should shape product selection here?

The article says a provider weighs efficacy data against your metabolic profile, affordability, and whether you prefer an injection or an oral formulation. It also notes that compounded formulations from licensed 503A pharmacies open up additional cost-effective routes. The point it presses is that selection is a clinical judgment made with you, not a matter of picking whichever brand is advertised most heavily.

Related Reading

• Glp 1 Drugs For Weight Loss
• Glp 1 For Weight Loss 2
• Glp 1 Weight Loss Before And After
• Glp 1 Dosage For Weight Loss

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.